Q-omics provides the consensus-scored CASKIN2 profile across patient tissues and cancer cell-line models. CASKIN2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CASKIN2 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, CASKIN2 RNA expression shows 19,800 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where CASKIN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CASKIN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CASKIN2 survival associations across molecular data types. CASKIN2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CASKIN2 RNA expression–survival associations across cancer types. High CASKIN2 expression shows unfavorable associations in LIHC, but favorable associations in KIRC, PAAD, LAML, LUAD and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CASKIN2 RNA expression.
This table summarizes CASKIN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CASKIN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CASKIN2 shows lower tumor expression in KICH, KIRC, LUAD and LUSC and higher tumor expression in LIHC and HNSC. The KICH box plot shows higher CASKIN2 RNA expression in normal versus tumor tissue (log2 FC = −1.567, t-test p < 0.001).
This table shows molecular features associated with CASKIN2 in patient tissues and cancer cell lines. In patient samples, CASKIN2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CASKIN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
